Document Detail


Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol.
MedLine Citation:
PMID:  20830766     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
BACKGROUND: Unresectable colorectal liver metastases have a 1- and 2-year survival of 55% and 33% with current systemic therapies. The authors evaluated response and survival after transarterial chemoembolization.
METHODS: Chemoembolization with cisplatin, doxorubicin, mitomycin C, ethiodized oil, and polyvinyl alcohol particles was performed at monthly intervals for 1 to 4 sessions. Cross-sectional imaging and clinical and laboratory evaluation were performed before treatment, 1 month after treatment, and then every 3 months. A second cycle was performed for intrahepatic recurrence. Toxicity was assessed using National Cancer Institute's Common Toxicity Criteria version 3.0. Response was evaluated using Response Evaluation Criteria in Solid Tumors criteria. Progression and survival were estimated with Kaplan-Meier analysis.
RESULTS: A total of 245 treatments were performed over 141 cycles on 121 patients. Ninety-five of 141 treatment cycles were evaluable for response: 2 (2%) partial response, 39 (41%) stable disease, and 54 (57%) progression. Median time to disease progression (TTP) in the treated liver was 5 months, and median TTP anywhere was 3 months. Median survival was 33 months from diagnosis of the primary colon cancer, 27 months from development of liver metastases, and 9 months from chemoembolization. Survival was significantly better when chemoembolization was performed after first- or second-line systemic therapy (11-12 months) than after third- to fifth-line therapies (6 months) (P = .03). Presence of extrahepatic metastases did not adversely affect survival (P = .48).
CONCLUSIONS: Chemoembolization provided local disease control of hepatic metastases after 43% of treatment cycles. Median survival was 27 months overall, and 11 months when initiated for salvage after failure of second-line systemic therapy. Cancer 2011. © 2010 American Cancer Society.
Authors:
Marissa Albert; Matthew V Kiefer; Weijing Sun; Daniel Haller; Douglas L Fraker; Catherine M Tuite; S William Stavropoulos; Jeffrey I Mondschein; Michael C Soulen
Related Documents :
19030196 - Cholangiocarcinoma: a compact review of the literature.
15660506 - Surgical therapy for metastatic disease to the liver.
14714186 - Results of surgical treatment for multiple (> or =5 nodules) bi-lobar hepatic metastase...
20095016 - Stereotactic body radiation therapy for colorectal liver metastases.
20648586 - Does serum carcinoembryonic antigen elevation in patients with postoperative stage ii c...
8791276 - Prognostic factors for response and survival in patients with metastatic melanoma recei...
Publication Detail:
Type:  Journal Article     Date:  2010-09-09
Journal Detail:
Title:  Cancer     Volume:  117     ISSN:  0008-543X     ISO Abbreviation:  Cancer     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2011-01-06     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0374236     Medline TA:  Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  343-52     Citation Subset:  AIM; IM    
Copyright Information:
Copyright © 2010 American Cancer Society.
Affiliation:
Division of Interventional Radiology, University of Pennsylvania, Philadelphia, Pennsylvania.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  17?-estradiol exposure accelerates skeletal development in Xenopus laevis tadpoles.
Next Document:  Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive blad...